




Global leaders in Arrhythmia, Pacemaker & ICD Management Software



CardioComm Solutions Inc.

Management Discussion and Analysis

For the nine months ended September 30, 2007
(Unaudited – Prepared by Management)



Management's Discussion and Analysis Financial Condition and Results of Operations

The following discussion of our consolidated financial condition and results of operations, as of September 30, 2007, has been prepared in accordance with Canadian generally accepted accounting principles (GAAP) and all amounts are expressed in Canadian dollars. The Management's Discussion & Analysis (MD&A) should be read in conjunction with the consolidated financial statements and accompanying notes to the consolidated financial statements for the nine months ended September 30, 2007, as well as the audited consolidated financial statements and MD&A for the fiscal year ended December 31, 2006.

The Company is a reporting issuer in British Columbia, Alberta, and Ontario, and trades on the TSX Venture Exchange under the symbol CCG.

The public documents of the Company can be viewed at the SEDAR website (www.sedar.com).

Overall Performance

Financial Condition:

- Q3 2007 revenue of \$149,397, a decrease of 73% as compared to \$560,518 in Q3 2006
- Q3 2007 net loss of \$243,099, a 539% increased loss as compared to Q3 2006 loss of \$38,069
- Q3 2007 net working capital deficiency of \$2,486,547, an increased deficiency of \$155,040 as compared to \$2,331,507 at 2006 year end

For the third quarter of 2007, CardioComm's financial results were reduced from Q3 2006 results. Revenue decreased by \$411,121 or 73% while expenses decreased by \$180,125 or 31% in Q3 2007 compared to Q3 2006.

Company Overview

The Company was incorporated under the laws of British Columbia, on October 26, 1989 and operated as a computer related consulting firm until 1991. In 1992, the Company commenced

activities in research and development of advanced software and hardware related to a personal heart arrhythmia monitoring system. Effective December 7, 1998, the Company's name was changed to CardioComm Solutions Inc. The Company is based in Victoria, British Columbia.

CardioComm is a public company listed on the Toronto Venture Stock Exchange under the stock symbol "CCG".

CardioComm's patented and proprietary technology is used in products for the recording, viewing, analyzing and storing of electrocardiograms (ECGs), for diagnosis and management of cardiac patients. CardioComm has achieved its technical goals of improved access and communication through the development of a real-time ECG viewer. CardioComm is the first company to provide a real-time means of viewing ECGs over a network (LAN, WAN or Internet). This tool enables ECGs to be viewed and controlled live, by physicians, over a global virtual healthcare network. This technology is marketed as Global ECG Management System (GEMS™) and GlobalCardio™. The U.S. Food and Drug Administration have cleared CardioComm's software products for sale in the United States. The Company has both ISO 9001:2000 and ISO 13485:2003 certifications.

Selected Annual Information

(in thousands of Canadian dollars)

Years ended	<u>2006</u>	<u>2005</u>	<u>2004</u>
Revenue	\$1,762	\$1,016	\$2,746
Net earnings (loss)	(625)	(1,542)	(404)
Loss per share	(0.02)	(0.04)	(0.01)
Total assets	427	203	686
Long-term liabilities	-	-	-

Results of Operations

For the Three Months ended September 30, 2007 compared to the Three Months ended September 30, 2006

Operating results expressed as a percentage of revenue:

Three months ended Sept 30,	2007	2006
Revenue	100%	100%
Expenses		
Administration	112	51
Sales and marketing	50	37
Product development	106	66
	<u>274</u>	<u>154</u>
Earnings (loss) from operations	(174)	(54)
Other income (loss)	11	1
Net earnings (loss)	<u>(163)%</u>	<u>(53)%</u>

Revenue by product:

Three months ended Sept 30,	2007	2006
Revenue by product		
Software	43%	81%
Support	57	13
Other	0	6
	<u>100%</u>	<u>100%</u>

Revenue by geographical region:

Three months ended Sept 30,	2007	2006
Revenue by region		
United States	78%	97%
Canada	10	2
Other	11	1
	<u>100%</u>	<u>100%</u>

Revenue

Revenue for the third quarter of 2007 was \$149,397 compared to \$560,518 for the third quarter of 2006, a decrease of 73%. The decrease in revenue is due to decreases in custom development and GlobalCardio sales, in Q3 2007 as compared to Q3 2006.

Cost of sales

Cost of sales decreased by 90% in the third quarter of 2007 as compared to the third quarter of 2006. The decrease is consistent with the

decrease of 73% of revenue in Q3 2007 as compared to Q3 2006. Costs of sales expenses are included in sales and marketing expenses. Q3 2007 amounts for cost of sales were \$9,237 as compared to \$81,541 for Q3 2006.

General and administrative

General and administrative expenses were \$166,679 for the third quarter of 2007, compared to \$169,144 for the third quarter of 2006; a decrease of 1% in Q3 2007, as compared to Q3 2006. The decrease in general and administrative costs in Q3 2007 is due to decrease in financing costs in Q3 2007, being somewhat offset by increases in professional / consulting costs.

Sales and marketing

Sales and marketing expenses were \$75,305 for the third quarter of 2007, compared to \$174,209 for the third quarter of 2006; a decrease of 57% for Q3 2007 compared to Q3 2006. The decrease in sales and marketing costs are due to decreased wages in marketing staff, decreased cost of sales and decreased travel costs in Q3 2007 compared to Q3 2006.

Product development

Product development expenses were \$167,594 in the third quarter of 2007, compared to \$246,350 for the third quarter of 2006, a decrease of 32% for Q3 2007 compared to Q3 2006. The decrease in product developments costs are due to less staff in product development in Q3 2007 compared to Q3 2006.

Net earnings

CardioComm recorded a net loss of \$243,099 or \$(0.01) loss per share in the third quarter of 2007, compared to a net loss of \$38,069 or \$(0.00) loss per share in Q3 2006. The increased loss for Q3 2007 was mainly attributable to a substantial decrease in sales of \$411,121 or 73%. The weighted average number of shares outstanding increased to 53,067,376 in Q3 2007, from 42,067,376 in Q3 2006 due to a private placement of February, 2007.

Results of Operations

For the Nine Months ended September 30, 2007 compared to the Nine Months ended September 30, 2006

Operating results expressed as a percentage of revenue:

Nine months ended Sept 30,	2007	2006
Revenue	100%	100%
Expenses		
Administration	80	51
Sales and marketing	40	37
Product development	85	66
	<u>205</u>	<u>155</u>
Earnings (loss) from operations	(105)	(55)
Other income (loss)	1	1
Net earnings (loss)	<u>(104)%</u>	<u>(54)%</u>

Revenue by product:

Nine months ended Sept 30,	2007	2006
Revenue by product		
Software	68%	80%
Support	32	19
Other	0	1
	<u>100%</u>	<u>100%</u>

Revenue by geographical region:

Nine months ended Sept 30,	2007	2006
Revenue by region		
United States	82%	88%
Canada	6	7
Other	12	5
	<u>100%</u>	<u>100%</u>

Revenue

Revenue for the nine months ended September 30, 2007 was \$768,363 compared to \$1,146,929 for the nine months ended September 30, 2006, a decrease of 33%. The decrease in revenue is due to significant decreases in GEMs software sales, as well as reduced GlobalCardio and custom development sales in the nine months ended September 30, 2007 as compared to the nine months ended September 30, 2006.

Cost of sales

Cost of sales decreased by 53% for the nine months ended September 30, 2007 as compared to the nine months ended September 30, 2006. Costs of sales expenses are included in sales and marketing expenses. For the nine months ended September 30, 2007 the cost of sales was \$67,739 as compared to \$142,892 for the nine months ended September 30, 2006.

General and administrative

General and administrative expenses were \$613,755 for the nine months ended September 30, 2007, compared to \$589,383 for the nine months ended September 30, 2006; an increase of 4% for the nine months ended September 30, 2007, as compared to the nine months ended September 30, 2006. The increase in general and administrative costs in 2007 is due to increases in professional fees and consulting costs.

Sales and marketing

Sales and marketing expenses were \$303,850 for the nine months ended September 30, 2007, compared to \$427,554 for the nine months ended September 30, 2006; a decrease of 29% for 2007 compared to 2006. The decrease in sales and marketing costs are due to decreased wages in marketing staff and decreased travel costs in 2007 compared to 2006.

Product development

Product development expenses were \$659,155 for the nine months ended September 30, 2007, compared to \$761,152 for the nine months ended September 30, 2006, a decrease of 123 for 2007 compared to 2006. The decrease in product developments costs are due to less staff in product development in 2007 compared to 2006.

Net earnings

CardioComm recorded a net loss of \$798,640 or \$(0.02) loss per share for the nine months ended September 30, 2007, compared to a net loss of \$616,817 or \$(0.02) loss per share for the nine months ended September 30, 2006. The increased loss for 2007 was mainly attributable to a significant decrease in sales of \$378,566, and was slightly offset by decreases in wages due to less staff in 2007. The weighted average number of shares outstanding increased to 51,294,482 in 2007 from 40,343,566 in 2006 due to a private placement in February, 2007.

Liquidity

Operating Activities

Cash used for operations was \$792,409 in the nine months ended September 30, 2007, compared to \$322,090 in the nine months ended September 30, 2006. The nine months ended September 30, 2007 had a loss of \$798,641 compared to a loss of \$616,817 in the nine months ended September 30, 2006. The large decrease of accounts payable and deferred revenue, and increase in accounts receivable in 2007 compared to 2006 resulted in the increase in the use of cash for operations in 2007.

Investing Activities

Cash used by investing activities was \$11,021 in the nine months ended September 30, 2007, compared to \$6,584 in the nine months ended September 30, 2006. Investing activities in 2007 were entirely capital expenditures consisting of mainly computer equipment and software.

Financing Activities

In February 2007, the Company completed a private placement, for 11,000,000 units at \$0.06 per unit, for total gross proceeds of \$660,000. Each unit consists of one common share of the Company and one common share purchase warrant. Each warrant is exercisable into one additional common share at an exercise price of \$0.10 per share on or before 24 months after the date of closing

Cash provided by financing activities was \$593,018 in the nine months ended September 30, 2007, compared to \$438,000 in the nine months ended September 30, 2006. The provision of cash in 2007 was due to a private placement of net proceeds of \$600,000, and \$3,018 of net advances from related parties, as well as repayments of \$10,000 of promissory notes.

Cash Requirements

Short-term cash requirements are primarily related to funding of operations and the only outstanding contractual obligation (Biomedical convertible note) matured in June of 2006 but has yet to be settled. The Company will be seeking further financing. See further under "Subsequent Events".

Off-Balance Sheet Arrangements

The Company does not utilize off-balance sheet arrangements.

Transactions With Related Parties

During the nine months ended September 30, 2007, the Company received \$47,850 advances and repaid \$44,832 of advances from related parties.

Subsequent Events

In January 2007, the Company announced that, subject to regulatory and shareholder approval, it will acquire all the issued and outstanding shares of CardioView, Inc. on a share for share exchange. Specifically, CardioComm will issue 10,000,000 common shares, to a maximum value of \$600,000 to the shareholders of record at closing in exchange for all the issued and outstanding shares of CardioView. This acquisition is expected to close in beginning of Q4 of 2007.

In October 17, 2007 the Company announced it will be undergoing a corporate reorganization which will enable the Company to pursue its business goals in an efficient and effective manner and to seek additional business opportunities.

The Company scheduled a special general meeting of the shareholders to be held at 2:30 p.m. on Thursday, November 15, 2007 at The Union Club of B.C., 805 Gordon St. in Victoria, British Columbia.

Share Consolidation: There are 63,067,376 common shares of the Company issued and outstanding (93,872,376 shares on a fully diluted basis). In the best interests of the Company, management has deemed it desirable for the Company to consolidate its outstanding common shares to make the Company attractive to new investors as well as to existing shareholders and to provide a foundation from which to advance the Company's business plan. For these reasons, management intends to consolidate the outstanding shares of the Company on a one-for-five (1:5) basis. After consolidation there will be 12,613,475 common shares

outstanding, subject to such adjustment to reflect rounding down of fractional shares and closing of the other business matters.

A requirement of the TSX Venture Exchange for the consolidation is that the Company change its name. The Company was given shareholder approval of a change of the Company's name to "CardioComm Solutions, Inc.", and the Company's trading symbol to "EKG" following the consolidation.

Alteration of Authorized Share Structure: In 2004, the *Company Act* (British Columbia) was repealed and replaced by the *Business Corporations Act* (British Columbia). Under the *Business Corporations Act* a company may specify an unlimited number of shares of each class that it is authorized to issue, which is allowed under most modern incorporation statutes, including the federal *Canada Business Corporations Act*. At present, the Company's authorized share structure consists of 100,000,000 common shares without par value. At the special general meeting of shareholders, the Company received shareholder approval to alter its authorized share structure by increasing the maximum number of common shares that it is authorized to issue from 100,000,000 common shares without par value to an unlimited number of common shares without par value. Management of the Company believes that this alteration will cause the Company's share structure to be similar to that of other similar companies existing under modern incorporation statutes.

Shares for Debt: As part of its corporate reorganization, the Company negotiated outstanding debt of the Company in the aggregate amount of \$1,601,826.14 to be settled in exchange for the issuance of an aggregate of 5,576,633 common shares of the Company (post-consolidation) to four creditors of the Company. 4,153,361 of the shares will be issued at a deemed issue price of \$0.30 per share, while 1,432,272 of the shares will be issued at \$0.25 because the debt being settled for those shares is secured by the assets of the Company. Consummation of

the shares for debt transaction was approved by the TSX Venture Exchange.

Equity Financing: The Company has secured a private placement equity investment with Anglo German Progressive Fund I (the "Fund") under which the Fund will purchase units of the Company (each unit consisting of one common share and one common share purchase warrant exercisable for two years for an additional common share) for an aggregate purchase price of \$1,400,000 in four tranches as follows: \$350,000 at a price of \$0.175 per unit for 2,000,000 units in October 2007; \$350,000 at a price of \$0.20 per unit for 1,750,000 units on December 1, 2007; \$350,000 on March 14, 2008 at a price per unit equal to the "Discounted Market Price" of the common shares of the Company on that date; and \$350,000 on June 16, 2008 at a price per unit equal to the "Discounted Market Price" of the common shares of the Company on that date. Under the policies of the TSX Venture Exchange, the "Discounted Market Price" of the Company's shares is the market price of the shares on the date of determination less: a discount of up to 25% of the market price if the market price is \$0.50 or less; or a discount of up to 20% of the market price if the market price is \$0.51 to \$2.00. In each of the third and fourth tranches, the units will be issued at the maximum allowable discount to the market price. The first tranche of the financing was in the form of a convertible note, which shall be convert into units upon the completion of the Company's share consolidation described above. The financing received both shareholder and TSX Venture Exchange approval.

Adoption of Share Compensation Plans: Shareholders and the TSX Venture Exchange approved the Company's adoption of a new 2007 Omnibus Share Compensation Plan, which will provide additional types of awards that can be granted by the Company to eligible recipients. An aggregate of 4,000,000 common shares (post-consolidation) will be reserved for issuance under the plan. Management of the Company believes that the plan will provide greater flexibility with share-based incentives for retaining

employees, directors and officers and will allow the Company to use its cash to develop the Company's business.

Software Development Agreement with MD Primer Inc.: The Company announced it has entered into a software development agreement with MD Primer Inc. Under the Agreement (1) the Company will be required to create certain software for MD Primer for total consideration of \$250,000; (2) the Company will be granted a non-exclusive license by MD Primer to use the software, subject to the payment of a royalty; and (3) all right, title and interest in the software may be purchased by the Company within two years of the date of the Agreement at the request of either party in exchange for the issuance by the Company of 1,000,000 units (post-consolidation) to MD Primer. Each unit will consist of one common share and one common share purchase warrant (exercisable for an additional share at a price of \$0.40 until July 27, 2008, and at a price of \$0.45 following that date until July 27, 2009, post-consolidation). The common shares issued to MD Primer by the Company for the software will be subject to escrow and will be released in accordance with the following schedule: 250,000 shares will be released immediately upon issuance of the shares; and an additional 250,000 shares will be released three months, six months and nine months from the date of the issuance of the shares.

MD Primer is wholly owned by Dr. Anatoly Langer, a director of the Company. The TSX Venture Exchange required the Company to obtain disinterested shareholder approval of the Company entering into the Agreement and of the issuance of securities of the Company to MD Primer under the Agreement, which was approved by at the special general meeting of shareholders the Company.

Acquisition of CardioView, Inc.: The Company completed its acquisition of CardioView, Inc. (as announced on January 31, 2007). Under the acquisition, the Company issued an aggregate of 10,000,000 common shares of the Company to

CardioView's shareholders in exchange for all of the issued and outstanding CardioView shares. The acquisition allows CardioComm to significantly increase and expand its product offerings. As CardioView has an established revenue base from research work done in Canada, CardioComm will expand the base and begin marketing the product in the US. The revenue model will become a user pay model similar to GlobalCardio™ 12 lead ECG version.

Critical Accounting Estimates

Revenue Recognition:

The Company recognizes revenue when it is realized or realizable and earned. The Company considers revenue realized or realizable and earned when it has persuasive evidence of an arrangement, the product has been delivered and is installed and operational at a customer's place of business or the services have been provided to the customer, the fee is fixed and determinable, and collectibility is reasonably assured. In addition to this general policy, the following are the specific revenue recognition policies for each major category of revenue.

Software:

Revenue from the sale of proprietary software is recognized when title is transferred to the customer. Shipping and handling costs paid by the customer to the Company are included in revenue.

Service:

Revenues derived from ongoing service and maintenance contracts are recognized monthly over the term of the contract on a straight-line basis and are net of discounts. Other service revenue is recognized at the time the service is performed.

Multi-element arrangements:

The Company also has multiple-element sales arrangements where software licenses, the associated post-contract services ("PCS") and services are sold together.

The Company has established vendor-specific objective evidence ("VSOE") of the fair value of PCS for specific customer classes based on the value of PCS when sold separately as an optional renewal after the expiry of the initial maintenance term or based on contracted prices

for optional PCS renewals included in the original multiple element sales arrangement.

The Company uses the residual method to determine the fair value of the delivered hardware, services and software license if VSOE of the fair value of all undelivered elements exists. Under the residual method, the fair value of the undelivered elements is deferred and the remaining portion of the arrangement fee is recognized as revenue. In such cases, when vendor-specific objective evidence of fair value exists for all of the undelivered elements (most commonly PCS), the residual amount is recognized as revenue and the PCS is recognized ratably over the PCS term, which is typically 12 months.

Stock Compensation:

The Company accounts for all stock-based payments and awards under the fair value method. Under the fair value based method, stock-based payments to non-employees are measured at the fair value of the consideration received, or the fair value of the equity instruments issued, or liabilities incurred, whichever is more reliably measurable. The fair value of stock-based payments to non-employees is periodically re-measured until counterparty performance is complete, and any change therein is recognized over the period and in the same manner as if the Company had paid cash instead of paying with or using equity instruments. The cost of stock-based payments to non-employees that are fully vested and non-forfeitable at the grant date is measured and recognized at that date.

Under the fair value based method, compensation cost attributable to awards to employees is measured at fair value at the grant date and recognized over the vesting period. Compensation cost attributable to awards to employees that call for settlement in cash or other assets is measured at intrinsic value and recognized over the vesting period. Changes in intrinsic value between the grant date and the measurement date result in a change in the measure of compensation cost. Compensation cost is generally recognized on a straight-line basis over the vesting period. The Company accounts for the fair value of the granted options on the consolidated statements of operations and deficit and is included in the determination of income.

Changes In Accounting Policies

Financial Instruments – Recognition and Measurement

Effective for interim and annual financial statements beginning on or after October 1, 2006, the new Handbook Section 3855 “Financial Instruments – Recognition and Measurement” prescribes that all financial instruments within the scope of the standard, including derivatives, be included on a company’s balance sheet. Contracts that can be settled by receipt or delivery of a commodity will also be included in the scope of the section. These financial instruments must be measured, either at their fair value or, in limited circumstances when fair value may not be considered the most relevant measurement method, at cost or amortized cost. It also specifies when gains and losses as a result of changes in fair value are to be recognized in the income statement. This new Handbook section will be adopted by the Company as of January 1, 2007 on a prospective basis. The Company does not expect this new requirement to have a significant impact on the Company’s consolidated financial statements.

Comprehensive Income

Effective for interim and annual financial statements beginning on or after October 1, 2006, the new Handbook Section 1530 “Comprehensive Income” requires that an enterprise present comprehensive income and its components in a separate financial statement that is displayed with the same prominence as other financial statements. This Section introduces a new requirement to present certain gains and losses temporarily outside net income. This Handbook section was adopted by the Company as of January 1, 2007 on a prospective basis.

Outstanding Share Data

Common shares

The total issued and outstanding common shares of the Company at September 30, 2007 are 53,067,376.

Options

The following options were outstanding at September 30, 2007; each option entitles the holder to purchase one common share of the Company:

<u>Exercise Price</u>	<u>Outstanding</u>	<u>Expiry Date</u>	<u>Exercisable</u>
\$0.15	370,000	5/08/2008	370,000
\$0.25	300,000	5/08/2008	300,000
\$0.40	300,000	5/08/2008	300,000
\$0.17	140,000	11/05/2008	140,000
\$0.17	525,000	12/18/2008	525,000
\$0.12	300,000	8/23/2010	300,000
\$0.10	1,100,000	05/15/2011	825,000
\$0.10	750,000	1/25/2012	375,000
	<u>3,785,000</u>		<u>3,135,000</u>

Warrants

The following warrants were outstanding at September 30, 2007; each warrant entitles the holder to purchase one common share of the Company:

<u>Exercise Price</u>	<u>Outstanding</u>	<u>Expiry Date</u>
\$0.18	2,600,000	05/15/2008
\$0.10	11,000,000	02/14/2009
	<u>13,600,000</u>	

Disclosure Controls and Procedures

The company's audit committee has reviewed and approved this Quarterly Report prior to its release. CardioComm Solutions is committed to providing timely, accurate and balanced disclosure of all material information about the company and to providing fair and equal access to such information. As at June 30, 2007, the company's management evaluated the effectiveness of the design and operation of its disclosure controls and procedures, as defined under the rules adopted by the Canadian securities regulatory authorities. In addition, the company's management has

assessed whether, during the 2007 fiscal year, there have been any significant changes in the company's internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, the company's internal control over financial reporting. Disclosure controls and procedures designed to ensure that information required to be disclosed in reports filed with securities regulatory authorities is recorded, processed, summarized and reported on a timely basis, and is accumulated and communicated to the company's management, including the CEO as appropriate, to allow timely decisions regarding required disclosure. Internal control over financial reporting is a process designed by, or under the supervision of, senior management to provide reasonable assurance regarding the reliability of financial reporting and preparation of the company's financial statements in accordance with Canadian generally accepted accounting standards.

The company's management, including the CEO, does not expect that the company's disclosure controls or internal control over financial reporting will prevent or detect all material misstatements due to error or fraud. Because of the inherent limitations of all control systems, an evaluation of controls can only provide reasonable, not absolute assurance, that all control issues and instances of fraud or error, if any, within the company have been detected. The company is continually evolving and enhancing its systems of controls and procedures. Based on the evaluation of disclosure controls, and assessment of changes in internal control over financial reporting, the CEO and CFO have concluded that, subject to the inherent limitations noted above:

The company's disclosure controls are effective in ensuring that material information relating to the company is made known to management on a timely basis, and is fairly presented in all material respects in this Annual Report.

Quarterly Results of Operations

The following tables contain unaudited consolidated statements of operations for each of the eight most recent quarters that have been prepared on a basis consistent with the audited consolidated financial statements contained in our fiscal 2006 Annual Report.

	Quarter Ended			
	Sep 30, 2007	Jun 30, 2007	Mar 31, 2007	Dec 31, 2006
Revenue	\$ 149,397	\$ 235,372	\$ 383,594	\$ 614,942
Expenses:				
General and administrative	166,679	209,766	237,311	256,034
Sales and marketing	75,305	105,379	123,166	108,841
Product development	167,594	238,398	253,163	250,467
	409,578	553,543	613,640	615,342
Earnings (loss) before undernoted	(260,181)	(318,171)	(230,046)	(400)
Other expenses:				
Foreign exchange gain (loss)	17,082	3,079	(10,403)	(7,912)
Earnings (loss)	\$ (243,099)	\$ (315,092)	\$ (240,449)	\$ (8,312)
Basic and fully diluted loss per share	\$ (0.01)	\$ (0.01)	\$ (0.01)	\$ (0.00)
Weighted average number of shares	53,067,376	53,067,376	47,689,598	42,067,376

	Quarter Ended			
	Sep 30, 2006	Jun 30, 2006	Mar 31, 2006	Dec 31, 2005
Revenue	\$ 560,518	\$ 316,601	\$ 269,810	\$ 187,542
Expenses:				
General and administrative	169,144	199,826	220,413	209,370
Sales and marketing	174,209	127,811	125,534	133,947
Product development	246,350	248,271	266,530	241,353
	589,703	575,908	612,477	584,670
Earnings (loss) before undernoted	(29,185)	(259,307)	(342,667)	(397,128)
Other expenses:				
Foreign exchange gain (loss)	(8,884)	24,719	(1,494)	(1,721)
Earnings (loss)	\$ (38,069)	\$ (234,588)	\$ (344,161)	\$ (398,849)
Basic and fully diluted loss per share	\$ (0.00)	\$ (0.01)	\$ (0.01)	\$ (0.01)
Weighted average number of shares	42,067,376	40,953,387	37,531,820	36,867,376